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Objective: Here we report a case of a splenectomized white woman with natalizumab-associated progressive
multifocal leukoencephalopathy (PML), occurring as early as after 11 infusions and provide blood fluorescence-
activated cell sorting (FACS) analyses before and after natalizumab treatment.
Design: This is a report of a single case with immunological studies.
Methods: Methods comprised neurologic examination, magnetic resonance imaging, and cerebrospinal fluid (CSF)
studies as well as immune cell FACS analyses from blood.
Results: Diagnosis of PML was established after positive John Cunningham virus (JCV) DNA was detected in the
CSF. An immune reconstitution inflammatory syndrome was treated with repeated cycles of steroid pulses and
intravenous immunoglobulins. Reduced numbers of memory B cells, which might play an important role in antiviral
immune response, were detected in the blood. Moreover the percentage of CD19+ B cells was elevated in our
post-splenectomy patient as compared to a control cohort of multiple sclerosis (MS) patients under natalizumab
therapy.
Conclusion: Splenectomy may increase the risk for the development of natalizumab-associated PML via effects
on the B cell compartment. It may be regarded as a risk factor in MS patients independent from the duration
of disease.
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B cellsBackground
Before the era of natalizumab as first monoclonal antibody
in multiple sclerosis (MS) therapy arose, progressive
multifocal leukoencephalopathy (PML), which is caused
by the John Cunningham polyoma virus (JCV), was more
or less exclusively seen in immunocompromised individ-
uals, especially those suffering from human immunodefi-
ciency virus (HIV) infection [1,2]. Natalizumab is a highly
effective treatment option for relapsing remitting MS with
positive data from the pivotal phase III trial yielding a
reduction in annual relapse rate by 68% and a reduction* Correspondence: Ralf.Linker@uk-erlangen.de
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reproduction in any medium, provided the orin disability progression over 42% versus placebo [3]. Yet,
a rare but potentially severe adverse event of natalizumab
is the development of PML. At present, there are more
than 350 cases of natalizumab-associated PML reported
worldwide, with an overall incidence of 2.5/1,000. Treat-
ment with unselective immunosuppressants displays an
independent epidemiologic risk factor for the develop-
ment of PML, especially after 24 months of treatment
duration [4]. These data suggest that the probability to
develop a PML might be associated with an impaired inte-
grity of the immune system. To date, the exact immune
factors contributing to an increased PML susceptibility
are still not clearly defined. In particular, there are no data
on the role of the spleen for immune responses against JC
virus in MS patients. The spleen plays a key role in the
homeostasis of the immune system. By linking the innate. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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defense that protects from infections [5]. In splenec-
tomized individuals, absolute lymphocyte counts are
persistently elevated due to an increase in the absolute
CD4, CD8, B cell, and natural killer (NK) cell numbers
[6]. Similar changes can be observed in natalizumab-
treated patients [7,8]. Moreover, natalizumab treatment
may elicit prominent effects on the composition of the
circulating B cell populations. In particular circulating B
cells and especially pre-B cells are most prominently
elevated among the immune cell subsets [9-11]. Likewise
dominant changes on the peripheral blood B cell compart-
ment have also been observed in splenectomized patients.
Natalizumab associated changes have been attributed to
the mobilization of hematopoetic precursor cells from the
bone marrow and a redistribution of cells due to the in-
hibition of leukocyte migration and homing to secondary
lymphoid organs [12-14]. Splenectomy and natalizumab
may thereby have synergistic effects on the immune cell
composition of the peripheral blood thus increasing the
risk for PML.
Methods
Peripheral blood mononuclear cells (PBMC) were isolated
by centrifugation on a Lymphoprep™ (Fresenius Kabi
Norge AS, Oslo, Norway) density gradient. To allow com-
parative longitudinal analysis, PBMC were immediately
cryopreserved. Blood from our PML patient had been
drawn 22 months before the primary diagnosis of PML. At
that time the patient was not treated with disease modify-
ing drugs (T0). The second blood sample (T1) was drawn
when the patient was hospitalized for PML, the third
sample (T2) was obtained 21 days later. Results of our
splenectomized patients were compared with a control co-
hort of MS patients under natalizumab therapy (mean age,
34.4 years; range, 24-43 years; female to male ratio, 3.5:1;
mean disease duration, 7.8 years; range, 2–16 years; mean
expanded disability status scale (EDSS), 2.95; range, 1.5-
5.5). After gentle thawing, cells were washed twice in
phosphate buffered saline (PBS) containing 0.1% sodium
azide and 1% bovine serum albumine, followed by Fc re-
ceptor blocking with human IgG (Sigma-Aldrich, Munich,
Germany). Afterwards, cells were incubated for 30 min
with specific monoclonal antibodies. The B cell gating
strategy of fluorescence-activated cell sorting (FACS)
analysis has been provided as Additional file 1: Figure S1.
The following anti-human monoclonal antibodies (clone)
and the respective isotype control antibodies were used (all
fluorochrome-conjugated): anti-CD19 FITC (HIB19, BD
Biosciences), anti-CD27 efluor®450 (O323, ebioscience),
anti-IgM PE (SA-DA4, ebioscience), anti-IgD PerCP-CY5.5
(IA6-2, Biolegend). Cells were analyzed on a FACSCanto™
II using the FACSDiva™ Software (BD Biosciences,
Heidelberg, Germany).Case presentation
At the age of 4 years, a now 34–year-old white woman
underwent splenectomy after a neonatal omphalitis with
portal vein thrombosis and esophageal varices. The inci-
dence of common infections during child- as well as
adulthood was not increased in comparison to healthy
persons indicating a generally intact immunological
response. At the age of 19 years, the patient noticed
sensory disturbances in the feet with unsteadiness both
of which resolved spontaneously. Five years later she
was admitted to an outside hospital due to a hemiparesis
of the left side where the diagnosis of a MS was
established. Magnetic resonance imaging (MRI) of the
brain revealed several periventricular lesions as well a
gadolinium-enhancing lesion. Analysis of cerebrospinal
fluid presented oligoclonal bands. At that time, an
immunomodulatory therapy with interferon beta 1a i.m.
was started. In the following 3 years, the patient suffered
from four further relapses. Each time, high dose intra-
venous methylprednisolone pulses were applied and the
patient recovered completely. After the fourth relapse,
EDSS was 2.0 (see clinical course in Figure 1A). Over
the following 5 years, adherence to disease-modifying
therapy was poor. Consequently, the patient presented a
severe relapse with paraparesis and EDSS progressed
from 2.0 to EDSS 6.0 (Figure 1A). At that time, loss of
her working ability as a clerk accountant was incipient
and the patient was no longer able to independently care
for her 9-year-old son. Thus, an escalation therapy with
natalizumab was initiated which led to stabilization of
the disease without further relapses and an improvement
of EDSS to 2.5 (Figure 1A). After the 11th application of
natalizumab, the patient developed a paresis of the right
leg, which was initially considered as a relapse at an out-
side clinic where the patient received a high dose intra-
venous methylprednisolone pulse without success. Upon
re-evaluation in our Department, the MRI scan of the
brain showed a linear fronto-parietal cortical lesion with
a very faint gadolinium enhancement (Figure 1B). A sub-
sequently performed cerebrospinal fluid analysis revealed
30 copies of JC virus DNA and the JC virus antibody
assay was positive (this test was not yet available at the
beginning of therapy). The patient immediately un-
derwent plasmapheresis therapy with five cycles for
natalizumab elimination. On the basis of expert recom-
mendations, a therapy with mirtazapine at a dosage of
60 mg and mefloquine 1,500 mg the first week and then
250 mg weekly was initiated. In the next months, re-
peated MRI scans after PML diagnosis of the brain
presented an increase of the right fronto-parietal lesion
volume with gadolinium enhancement (Figure 1B).
These findings correlated with the development of a
paresis oft the right hand and focal epileptic seizures of
the right hand, indicating the clinical deterioration of
Figure 1 Frequency of B cells and B cell subgroups before and after natalizumab treatment. (A) Schematic overview of the clinical course
of MS and PML in our splenectomized patients. PE, plasma exchange. (B) MRI over the course of disease. On admission, an axial flair-attenuated
inversion recovery (FLAIR)-weighted scan of the brain displayed signal hyperintense lesion in the frontal- parietal lobe (arrow), 3 weeks after
diagnosis lesion volume increased in the course of the IRIS, 6 weeks after diagnosis nearly the whole frontal- parietal lobe is affected (arrow).
T1-weighted images with Gd displayed a very faint Gd enhancement (arrow), 3 weeks after diagnosis and 6 weeks after diagnosis lesion volume
with Gd enhancement increased (arrow). (C) The percentage of CD19+ cells within the lymphocyte gate was assessed by flow cytometry in
relapsing-remitting MS (RRMS) patients with active disease before and 3 to 6 months after initiation of Natalizumab therapy (n = 14) and in the
splenectomized patient. Different time points marked by a cross; T0, before natalizumab therapy; T1, at the time of PML; T2, 3 weeks after PE.
(D) The percentages of specialized B cell subpopulations (CD19 + CD27+ memory cells, IgM + memory cells, and IgM + IgD + marginal cell-like
B cells) were assessed by flow cytometry in natalizumab-treated RRMS control patients (n = 5; mean + 95% CI) and the splenectomized PML patient at
different time points marked by a cross. T0, before natalizumab therapy; T1, at the time of PML; T2, 3 weeks after PE. (E) Dot blot of CD19 + CD27+
memory B cells within the lymphocyte gate in the splenectomized patient and a representative, natalizumab-treated RRMS control.
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flammatory syndrome (IRIS) after elimination of natalizu-
mab. An antiepileptic therapy with levetiracetam was
started and the patient received repeated high-dose meth-
ylprednisolone intravenously (total dosage of 20,000 mg in
three cycles, see Figure 1A). Six weeks after diagnosis of
PML was made, EDSS deteriorated from 4.0 to 6.5 and
the patient additionally showed symptoms of major de-
pression. Six months after the diagnosis of PML, MRI
scans of the brain for the first time revealed a reduction of
lesion volume and gadolinium enhancement (Figure 1B).
No further focal epileptic seizures occurred and the par-
esis of the right hand as well as symptoms of depression
completely resolved. Nine months after diagnosis of PML,
the patient started to work again, although EDSS was still
5.5. The last MRI scan performed 10 months after diag-
nosis of PML revealed one new periventricular lesion
without gadolinium enhancement. The PML lesion still
showed a slight gadolinium uptake while lesion volume
did no change any more (Figure 1B). So far, the patient
refused to re-start any new immunomodulatory therapy.
Using flow cytometry, we analyzed the percentage of
CD19 positive (+) B cells within the lymphocyte gate in
active MS patients before and 3 to 6 months after initiation
of natalizumab therapy (n = 14). Before treatment, CD19+
B cells accounted for 14.2 ± 5.5% of lymphocytes (361 ±
159 cells/μL) and increased to 21.8 ± 5.5% (876 +/− 325
cells/μL) under natalizumab therapy. In contrast, the per-
centage of CD19+ B cells in our splenectomized patient
was 35.1% (576/μL) even before starting on natalizumab
(T0; >3-fold SD) (Figure 1C). At the time of PML (T1) the
percentage of CD19+ B cells within the lymphocyte gate
had increased to 44.2% (approximately four-fold SD of
natalizumab-treated patients; 1,303/μL) and remained high
even after plasma exchange (PE) (T2; 52.0%, 15 days post
PE; 868/μL) (Figure 1C). B cell subpopulations were further
analyzed in n = 5 natalizumab-treated MS patients without
PML. A total of 34.2 ± 11.2% of CD19+ B cells displayed a
CD27+ memory phenotype which is within the range of
published data on memory B cells in these patients [4]. In
contrast, the percentage of CD27+ memory B cells was
considerably lower in our patient both before natalizumab
(T0; 10.5% of CD19+ cells) and at the time of PML (T1;
11.3% of CD19+ cells) (Figure 1D and E). Following PE, we
observed a disproportional rise in CD27+ memory B cells
(T2; 29.4% of CD19+ cells) (Figure 1D and E). Comparable
observations were made for the IgM + population of
memory B cells (T0; 10.8, T1; 11.5%, T2; 23.2%, data given
as % of memory cells). In contrast, IgM + memory B cells
accounted for 40.0 ± 10.9% of memory B cells in our
natalizumab-treated control group. Marginal cell-like
CD19+ CD27 + IgM + IgD + B cells accounted for 36.2 ±
15.2% of B cells in the natalizumab group, which is within
the range of previously published data on long-termtreated patients [4] (Figure 1D). In our patient, the per-
centage of marginal cell-like B cells tended to be lower as
compared to the controls (T0, 20.2%; T1, 20.9%; T2, 29.0%)
but was still within the two-fold of standard deviation of
the controls.
Discussion
Although the development of PML under natalizumab is
extremely rare in the first year of therapy even in patients
with a history of immunosuppression, this immunosup-
pressant-therapy naïve splenectomized MS patient deve-
loped a PML after only 11 infusions.
B cells are susceptible to JC virus infection and have
been implicated in the reactivation and central nervous
system (CNS) transmigration of the virus. Following the
start of natalizumab therapy, the percentage of circulat-
ing B cells increases disproportionately [9,10]. A select-
ive mobilization of B cells may thus be relevant for PML
development by propagation of JCV dissemination. In
addition, B cells may serve as a carrier that transports
the virus to the CNS [15]. The spleen is regarded the
most important reservoir of memory B cells. In addition,
the spleen is the tissue that, if tested positive for JCV
DNA, harbors the highest diversity of sequence rear-
rangements within the JCV regulatory region [9,16-18].
Splenectomy has wide-ranging consequences for immune
cell homeostasis. Especially the B cell compartment seems
to be affected. The percentage of CD19+ B cells among
the lymphocyte population may be elevated in some but
certainly not all post-splenectomy patients irrespective of
the reason for splenectomy, that is trauma or hematolo-
gical disease [19,20]. Yet, an increase in the percentage of
circulating B cells is per se not considered a risk factor for
infection in post-splenectomy patients. Our patient had
an extraordinary high percentage of CD19+ lymphocytes
within the peripheral blood that - as would be expected -
even further increased under the influence of natalizumab.
Given the possible role of B cells in JC virus propagation,
we cannot exclude that the high pre-treatment percentage
of B lymphocytes may have contributed to PML in our
patient. However, the perturbed B cell memory compart-
ment may have been the more crucial factor. Our patient
had low percentages of both CD27+ and CD27 + IgM +
memory B cells. This is a common finding following
splenectomy [5,19]. Assessing IgM memory B cell fre-
quency has therefore been proposed as a potential param-
eter for evaluation of splenic function or risk of infection
following splenectomy [19,21]. Natalizumab treatment
was reported to selectively mobilize memory B cells in MS
patients which was considered to be secondary to an im-
paired retention of memory cells in the splenic marginal
zone and gut-associated lymphoid tissue (GALT) by
blocking very late antigen (VLA)-4/vascular cell adhesion
molecule (VCAM)-1 interaction and downregulation of
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alpha4-beta1 integrin [9]. In our splenectomized patient,
memory B cell levels remained low under natalizumab
therapy and only increased after PE. Similar observations
were made for CD27 + IgM + IgD + B cells that tended to
be lower in our patient. These circulating marginal zone-
like B cells are considered to derive from the splenic
marginal zone where these cells play an important role in
the generation of T cell independent antibody responses
[22]. The source for the increase in memory B cells 3
weeks following natalizumab elimination by PE in our
patient is not clear but may be attributed to the GALT.
We here present data of one individual only, which is a
limitation of this study. In addition, our patient had been
treated with glucocorticoids before diagnosis of PML was
established. Since glucocorticoid treatment may affect
immune cell composition of the peripheral blood, we
cannot exclude that this has biased our findings. However,
the profound reduction of the memory B cell population
has repeatedly been demonstrated in splenectomized pa-
tients and therefore more likely to be due to the status
post-splenectomy and not the glucocorticoid treatment
[19]. Thus, given the prominent role of memory B cells in
antiviral immune responses, splenectomy may represent a
risk factor for PML under natalizumab therapy.
Conclusions
Splenectomy may increase the risk for the development of
natalizumab associated PML affecting the B cell compart-
ment and should regarded as a risk factor in MS patients
independent from the duration of disease. If therapy with
natalizumab is considered in a splenectomized MS patient,
benefits of the therapy should be well balanced with the
possibly increased risk for the development of PML.
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